💫🌟🔥 Hot off the press (Comments & Controversies)🌟💫 Thrilled to see the timely piece 👉 “Precision Oncology and Modernizing Evidence Standards” 🔑 Key takeaways: 🔵 RCT-only frameworks miss the reality of #PrecisionMedicine 🟢 Basket, umbrella & N-of-1 trials are cornerstones of #PrecisionOncology

🚨 NEJM | Sept 2025 Low-dose aspirin in PI3K-altered localized #ColorectalCancer (ALASCCA) “Low-dose aspirin cut 3-yr recurrence by ~50% in PI3K-altered localized colorectal cancer.” www.nejm.org/doi/full/10....

💫🌟🎓🆕Immune activation & ICI-related fatigue New study (JHU + Genentech) ✅ 58.5% of pts on ICIs reported fatigue ✅ Fatigue linked to ↑ Th1 cytokines (IFN-γ, IL-2, IL-12) ✅ Expansion of CD8+ effector T cells ✅ Fatigue = surrogate of immune activation

🧓👵 Geriatric assessment vs clinical evaluation in MM J Geriatr Oncol (Sept 2025, Raddoux et al.) 👏 Congrats to the authors & to the #GeriOnc community advancing care for older #MM patients. 📊 Prospective study in 200 older adults w/ newly diagnosed #MultipleMyeloma

ELEVATE-ing clinical trial reporting in CLL buff.ly/FwUhcEw #hemesky

Breast Cancer in Young Women: When, Why, and How? Melissa Troester, Kornelia Polyak, and Sherene Loi will address this question in an educational session at #SABCS25 (December 9-12). Learn more: buff.ly/OB6T5Xs @loisher.bsky.social

🧠 Neurotoxicity in Cancer Therapy New review (Nat Rev Clin Oncol) ✅ Pathophysiology of chemo-, RT- & IO-induced neurotoxicity ✅ Clinical recognition & biomarkers ✅ Prevention & management strategies 🔍 Key messages – Cavaletti, Cámara, DeAngelis et al. Nat Rev Clin Oncol 2025

📑 New ESMO CPG on Lymphomas ✅ Updated dx & staging recs ✅ 1L & r/r treatment algorithms ✅ Integration of CAR-T, bispecifics & BTKis www.annalsofoncology.org/article/S092...

Functional synapses between neurons and small cell lung cancer www.nature.com/articles/s41...

The @fda.gov has approved the gemcitabine intravesical system (Inlexzo) for adults with BCG-unresponsive non–muscle-invasive bladder cancer with CIS with/without papillary tumors. In the SunRISe-1 trial: complete responses reported in 82% ascopost.com/news/septemb...

🕯️ Today, we pause to remember the lives lost on September 11, 2001, and honor the courage of first responders, survivors, and families whose lives were forever changed. May we continue to carry forward the lessons of unity, resilience, and compassion.

🌟🟠 HER2 in mCRC New pooled analysis in JCO (8 RCTs, n=1,604)🌟 ✅ HER2+ = worse PFS & OS ❌ Not predictive for Bev vs anti-EGFR ➡️ Prognostic, not predictive #GIOnc #ColorectalCancer #mCRC #HER2 #Oncology #JCO #Medicalwatch ascopubs.org/doi/10.1200/...

🟢 Hepatocellular carcinoma (HCC) – 2025 global insights 🌍 New open-access review (Mauro, de Castro, Zeitlhoefler, Villanueva, Mazzaferro, Llovet et al.) 🔑 Highlights: ✅ 3rd leading cause of cancer death ✅ Etiology shift → viral ↓ | ALD & MASLD ↑ ✅ Prevention: HBV vax + antivirals effective

We are excited to announce the 2026 SITC EU Immuno-Oncology Drug Development Summit. Coming Sept. 2026 in Lausanne, Switzerland. This program will discuss best practices for modern IO drug development & the next wave of IO therapeutics. Join the waitlist: t.co/JhPLTpSvdb 🧪

Studying cancer evolution needs multi-region or single cell seq for phylogenetics, right? Amazingly (I think!) we found single-sample bulk methylation suffices, via analysis of "fluctuating methylation". In @nature.com today led by brilliant @calumgabbutt.bsky.social www.nature.com/articles/s41...

WU Hoo! The Promise of Allogeneic WU-CART-007 in Relapsed/Refractory T-Cell Malignancies url: ashpublications.org/thehematolog...

📢 European Journal of Cancer – New Research Cost-effectiveness of perioperative Durvalumab + Gem/Cis in MIBC (Germany) 📊 Results: ➡️ Cost: €113,224 (SoC) → €126,386 (+€13,162) ➡️ QALYs: 3.16 → 3.37 (+0.21) ➡️ ICER: €61,006/QALY ➡️ WTP €100,000 → 76.5% probability of cost-effectiveness

The Cancer Planners Forum 2025, hosted by @uiccofficial.bsky.social with @who.int, @iaeaorg.bsky.social, etc held in May 2025 raised urgent global needs for cancer control plans. Ulrika Årehed Kågström tells The ASCO Post about successes and remaining challenges ascopost.com/news/septemb...

Manage toxicities associated with bispecific tarlatamab for small cell lung cancer! Learn from a panel of experts during SITC’s #virtual Advances in Cancer Immunotherapy: A Focus on Lung Cancers program Sept. 12. Learn more: ow.ly/I7HJ50WT8wW 🧪 @drjnaidoo.bsky.social

🌍 #MWGlobalOnc Prognosis & biology of ER-low metastatic breast cancer – TONIC & multicenter cohort 🔑 Key Messages: ✅ ER-low (1–9%) behaves biologically closer to TNBC than ER+/HER2− ✅ Worse OS vs ER+/HER2−; prognosis similar to TNBC ✅ Phenotypic switch from ER+ → ER-low at relapse = poor outcomes

📚 #MWPaperFriday Geriatric Assessment: ASCO Global Guideline 🔑 Key Messages: ✅ GA identifies vulnerabilities missed by standard oncology evals ✅ Guides treatment tailoring, ↓ toxicity & ↑ QOL in older adults ✅ Universal GA recommended in all ≥65y pts w/ cancer

#SITC25 Science Preview: Join Drs. Michael Lotze @news.upmc.com, Wim Vos, Stephane Champiat @mdanderson.bsky.social, Eric Deutsch @gustaveroussy.fr & Di Dong in the session, “Imaging, Radiomics and Integrated Biomarkers in IO”. View session details: www.sitcancer.org/2025/schedul...

Fantastic to have this critical advice for older people with cancer - thank you @crisbergerot.bsky.social @bogda-koczwara.bsky.social and team

MD Anderson researchers developed a new single-cell DNA and RNA sequencing technology to identify ancestral breast cancer cells. How this can help gain understanding on why some breast cancers are more aggressive than others: spr.ly/6012A8cXg #OncSky #EndCancer

New Journal for ImmunoTherapy of Cancer position article and guidelines: Constructing the cure: engineering the next wave of antibody and cellular immune therapies bit.ly/3HYCbrs #JITC #ImmunoSky #MedSky

🎥 #MWVisualAbstract Surgical complexity after NACT in primary ovarian cancer ✍️ Chiara Ainio, Marina Rosanu, Lucia Ribero, Amanda L. Tapia, Giovanni D. Aletti, William A. Cliby et al. 🔶 Key Messages: ➡️ >50% of pts undergoing IDS after NACT required advanced procedures

Stay in the know with #SITC! Explore our upcoming events, webinars, and important dates by looking at our calendar. Learn More: sitcancer.org/get-involved... #Immunotherapy

In patients with SLE, the adaptive immunity reconstituted faster after CAR T-cell therapy than in patients with B-NHL. buff.ly/6i0bDpC #hemesky

💡 #MWClinicalTips FGFR1-amplified colorectal cancer: a distinct prognostic subtype ✅ Large-scale profiling (n=7606) → FGFR1 amplification = predominant FGFR alteration in CRC (≈4%). ✨ Independent marker of poor prognosis: ↓DFS (HR 2.91) & ↓PFS (HR 2.52).

#COTipTuesday 🔵 Prostate Cancer Statistics 2025 – CA Cancer J Clin ✅ 313,780 new cases & 35,770 deaths expected in US (2025) ✅ Incidence ↑ 3%/yr since 2014, driven by advanced-stage dx ✅ Distant-stage PCa rising across all ages 📈 ✅ Black men: 67% ↑ incidence & ~2x mortality vs White men

🟢 Circulating KIM-1 in adjuvant #RCC New Annals of Oncology analysis (IMmotion010): ✅ Elevated post-nephrectomy plasma KIM-1 = ↑ recurrence risk (HR 1.68) ✅ KIM-1high pts benefited from adjuvant atezo (HR 0.72)

🌟🫁 Early & locally advanced #NSCLC – New @myESMO Guidelines🌟 ✅ Screening: LD-CT for heavy smokers (55–74y) ✅ Biomarkers: EGFR, ALK & PD-L1 testing essential ✅ Surgery: Sublobar resection ≈ lobectomy for ≤2cm tumors

🌟🧠 #MWThinkWednesday Geriatric Assessment: ASCO Global Guideline 🌟 ✅ GA is recommended for all adults ≥65 receiving cancer treatment ✨ Identifies vulnerabilities beyond chronological age (function, comorbidities, polypharmacy, nutrition, cognition, psychosocial health)

🧠 #MWThinkWednesday Inferior control arms in oncology trials in LMICs: contextualised or compromised? ✅ Some oncology trials in LMICs still use inferior control arms vs HIC standards. ✅ Raises ethical concerns: are we contextualizing care or compromising patients?

Welcome to THIS Weeks @oncoalert @vjoncology JOURNAL CLUB: Brain Mets in #BreastCancer 👉 youtu.be/oZiYqHnKBYk?... A pleasure to present Dr. @elenalaakmann of University Medical Center Hamburg-Eppendorf discussing her paper on Brain imaging screening in metastatic Breast Cancer

💡 #MWClinicalTips Brain imaging screening in metastatic breast cancer: patients’ & physicians’ perspectives ✅ 529 physicians (50 countries): 65% request BIS in asymptomatic MBC, mainly for HER2+ & TNBC

🌍 #MWGlobalOnc Artificial intelligence across the cancer care continuum ✅ AI transforms oncology from prevention → survivorship → end-of-life care ✨ Early detection: deep learning predicts pancreatic & lung cancer risk yrs before diagnosis

Early-onset gastrointestinal cancers: comprehensive review and future directions academic.oup.com/bjs/article/...

🌟🚀 Novel trial designs in the era of molecular oncology🌟 🔑 Key insights: ✅ Molecular reclassification is reshaping cancer trial paradigms ✅ Basket & umbrella designs accelerate drug development across tumor types ✅ Adaptive, platform & seamless trials enable faster, more efficient testing

🧬 New AML care update for unfit patients Ven + HMA = current backbone ⚡️ CR/CRi ~40–90%, 3-yr OS up to 67% 📈 (better w/ NPM1, IDH2; worse w/ TP53, FLT3-ITD) Future: refine triplets ➕ optimize dosing, ASCT timing, & add PROs 🗣️ www.nature.com/articles/s41...

I agree with most of this although remain skeptical about predictions made by AI, or that certain preclinical studies can be completely eliminated. Securing America’s Pharmaceutical Innovation Edge Scott Gottlieb, MD jamanetwork.com/journals/jam...

🧬 New AML care update for unfit patients Ven + HMA = current backbone ⚡️ CR/CRi ~40–90%, 3-yr OS up to 67% 📈 (better w/ NPM1, IDH2; worse w/ TP53, FLT3-ITD) Future: refine triplets ➕ optimize dosing, ASCT timing, & add PROs 🗣️ www.nature.com/articles/s41...

💡 #MWClinicalTips 📢 Advances in Neuroendocrine Tumors (NETs) — therapeutic landscape update ✅ NETs are highly heterogeneous — site of origin & biology determine management. ✅ Somatostatin analogs remain backbone for symptom & tumor control.

New #cancer #neuroscience study revealing axonal injury as a driver of brain tumors 🧠 Another striking example of the mechanistic connection between #injury and tumor #progression 🧪🔬 Clements et al, Nature 2025 www.nature.com/articles/s41...

Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results www.nature.com/articles/s41...

💡 #MWClinicalTips 📢 Advances in Neuroendocrine Tumors (NETs) — therapeutic landscape update ✅ NETs are highly heterogeneous — site of origin & biology determine management. ✅ Somatostatin analogs remain backbone for symptom & tumor control.

Nature Medicine celebrates 30 years 🎉 with a wonderful series on the #FutureofMedicine ⚕️🧪 It was a privilege to contribute to this collection of diverse pieces, and reflect on a study we published there in 2013 - on the re-education of tumor-associated macrophages www.nature.com/collections/...

#ASHTriviaTuesday 🩸❓ : Test your knowledge with clinical case-based trivia from the NBME Hematology In-Service Exam. Share your insights in the comments! #HematologyTrivia #MedicalEducation #Hematologists

BCLAF1 is a novel transcriptional regulator that promotes HSC expansion during fetal development and after stem cell transplant. buff.ly/xzn35Kz #hemesky

💡 #MWClinicalTips 📢 IMvigor011 trial: ctDNA-guided adjuvant immunotherapy in MIBC. Natera & Genentech/Roche ✅ Signatera-positive pts + atezolizumab → significant ↑ DFS & OS ✅ Signatera-negative pts → excellent outcomes w/out adjuvant Rx